High sensitivity to tolvaptan in paraneoplastic syndrome of inappropriate ADH secretion (SIADH)

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 22; no. 12; p. 2696
Main Authors Kenz, S., Haas, C.S., Werth, S.C., Bohnet, S., Brabant, G.
Format Journal Article
LanguageEnglish
Published Oxford Elsevier Ltd 01.12.2011
Oxford University Press
Subjects
Aged
Aged, 80 and over
Antineoplastic agents
Benzazepines - therapeutic use
Biological and medical sciences
Female
Humans
Inappropriate ADH Syndrome - drug therapy
Inappropriate ADH Syndrome - mortality
Lung Neoplasms - drug therapy
Lung Neoplasms - mortality
Male
Medical sciences
Middle Aged
Natriuretic Agents - therapeutic use
Paraneoplastic Endocrine Syndromes - drug therapy
Paraneoplastic Endocrine Syndromes - mortality
Pharmacology. Drug treatments
Small Cell Lung Carcinoma - drug therapy
Small Cell Lung Carcinoma - mortality
Tolvaptan
Treatment Outcome
Sensitivity
Tolvaptan
Secretion
Neurohypophyseal hormone
Peptidergic receptor
V2 vasopressin receptor
Paraneoplastic syndrome
Antagonist
Neuropeptide
Vasopressin
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Feature-1
ObjectType-Correspondence-3
ISSN:0923-7534
1569-8041
DOI:10.1093/annonc/mdr431